Paperplane Therapeutics develops therapeutic virtual reality solutions to manage pain and anxiety in healthcare, targeting the North American dental market. Its immersive VR platform is designed for patients of all ages with an emphasis on pediatric care, aiming to improve patient comfort, streamline clinical workflows, and reduce clinician burden. The company positions its technology to transform dental procedures into more manageable experiences and address widespread dental anxiety—citing that about 36% of individuals experience anxiety during dental visits, 12% suffer extreme dental fear, and 22% postpone appointments. Paperplane is Quebec-based. The company closed a $1.5 million funding round to continue deploying VR therapies in the dental sector across North America. The investment will also support expansion into Europe through a strategic partnership with French company HypnoVR and its CE Marking certification.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2025